Brought to you by 
Forma raises $25.5mm through Series B round
02 Dec 2009
Executive Summary
Forma Therapeutics (transformative biology and chemistry technologies for cancer drug discovery) raised $25.5mm through its Series B round. New investors Lilly Ventures and Forma's development partner Cubist Pharmaceuticals were joined by existing buyers Novartis Option Fund, Bio*One Capital, and two additional unnamed investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forma raises $25.5mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice